<DOC>
	<DOCNO>NCT02575404</DOCNO>
	<brief_summary>This study dose escalation GR-MD-02 standard therapeutic dose pembrolizumab patient advance melanoma .</brief_summary>
	<brief_title>GR-MD-02 Plus Pembrolizumab Melanoma Patients</brief_title>
	<detailed_description>This study employ 3+3 phase I design dose escalation GR-MD-02 conjunction standard therapeutic dose pembrolizumab patient advance melanoma progression ipilimumab and/or BRAF target therapy BRAF mutation present . In addition monitoring toxicity clinical response , blood tumor sample obtain assess immunologic measure relevant galectin biology pembrolizumab T-cell checkpoint inhibition .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Patients metastatic unresectable melanoma treatment pembrolizumab indicate . Histological confirmation melanoma require previous biopsy cytology . Patients radiographic progression use Response Evaluation Criteria In Solid Tumors ( RECIST ) currently pembrolizumab also eligible . Patients must â‰¥ 18 year age . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Women childbearing potential must serum urine pregnancy test perform within 72 hour prior start protocol treatment . The result test must negative order patient eligible . In addition , woman childbearing potential well male patient must agree take appropriate precaution avoid pregnancy . No active bleeding . Anticipated lifespan great 12 week . Patients must sign studyspecific consent document . Patients previously receive galectin antagonist Patients active autoimmune disease except autoimmune thyroiditis vitiligo Patients history colitis Patients untreated brain metastasis . Patients treat brain metastasis demonstrate control brain metastasis followup image 4 week initial therapy eligible . Other active metastatic cancer require treatment . Patients active infection require antibiotic . Pregnant lactate woman , treatment involve unforeseeable risk embryo fetus . Need chronic steroid . Inhaled corticosteroid acceptable . Laboratory value ( perform within 28 day enrollment ) outside protocolspecified range . Inability give inform consent comply protocol . Patients history psychiatric illness must judge able understand fully investigational nature study risk associate therapy . Any medical condition opinion Principal Investigator would compromise safety conduct study procedure . Unresolved immunemediated pneumonitis , diarrhea , elevation hepatocellular enzyme toxicity require great physiological replacement dos steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Keytruda</keyword>
	<keyword>pembrolizumab</keyword>
	<keyword>GR-MD-02</keyword>
	<keyword>Galactoarabino-rhamnogalacturonate</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>